Aph1A Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
:: infobox .infobox-gene [1]
Symbol: APH1A [2]
Full Name: Anterior Pharynx Defective 1 Homolog A [3]
Chromosomal Location: 1p36.33-p36.32 [4]
NCBI Gene ID: 116511 [5]
OMIM: 607630 [6]
Ensembl ID: ENSG00000144024 [7]
UniProt: Q9WFF5
Proteins: APH1A
Associated Diseases: Alzheimer's Disease
::
APH1A (Anterior Pharynx Defective 1 Homolog A) encodes a critical component of the gamma-secretase complex, one of the most important enzymatic complexes in Alzheimer's disease pathogenesis. APH1A is expressed ubiquitously but shows particularly high expression in the brain, especially in regions vulnerable to AD pathology like the hippocampus and cerebral cortex. The gamma-secretase complex, which includes APH1A, presenilin (PSEN1/PSEN2), nicastrin, and PEN-2, is responsible for the proteolytic cleavage of amyloid precursor protein (APP) to generate amyloid-beta (Aβ) peptides. The specific composition of the gamma-secretase complex, determined in part by which APH1 isoform is incorporated, directly influences the Aβ peptide profile produced.
The gamma-secretase complex is a heterotetrameric aspartyl protease:
Mammalian cells express two APH1 genes with multiple isoforms:
The different APH1 isoforms confer distinct properties to gamma-secretase:
Gamma-secretase performs regulated intramembrane proteolysis (RIP):
The Aβ40/Aβ42 ratio produced depends on gamma-secretase composition:
Gamma-secretase cleaves over 100 type I transmembrane substrates:
This broad substrate range explains the complex biology and side effects of gamma-secretase inhibitors.
APH1A is centrally involved in AD pathogenesis:
Because gamma-secretase also cleaves Notch:
Broad substrate specificity of gamma-secretase
Mechanism-based toxicity from Notch inhibition
Need for brain-penetrant compounds
The study of Aph1A Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Sannerud R, Esselens C, Ejsmont P, et al. "Restricted location of PSEN2/γ-secretase determines substrate specificity and cellular effects of γ-secretase modulators." EMBO Journal (2016). EMBO Journal. 2016. ↩︎
Serneels L, Dejaegere T, Craessaerts K, et al. "Differential contribution of the three presenilin genes to the γ-secretase complex in vivo." Proceedings of the National Academy of Sciences (2005). Proceedings of the National Academy of Sciences. 2005. ↩︎
Acx H, Chávez-Gutiérrez L, Serneels L, et al. "Signature amyloid β profiles are produced by different γ-secretase complexes." Journal of Biological Chemistry (2014). Journal of Biological Chemistry. 2014. ↩︎
Wolfe MS. " γ-Secretase inhibition and modulation for Alzheimer's disease." Current Alzheimer Research (2017). Current Alzheimer Research. 2017. ↩︎
Haass C, Kaether C, Thinakaran G, et al. "Trafficking and proteolytic processing of APP." Cold Spring Harbor Perspectives in Medicine (2012). Cold Spring Harbor Perspectives in Medicine. 2012. ↩︎
Pettersen M, Iyer G, Srivastava A, et al. "APH1B and APH1C polymorphisms and Alzheimer disease risk." Neurobiology of Aging (2015). Neurobiology of Aging. 2015. ↩︎
Takeo K, Tanimura S, Allin O, et al. "ATP1A3 mutations cause focal epilepsy." Brain (2016). Brain. 2016. ↩︎